Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Morphea, a localized skin condition, is linked to a significantly higher cancer risk, according to a new study in JAMA Dermatology. Researchers found that over 12% of morphea patients developed cancer — with elevated risks for solid tumors and female reproductive and breast cancers in particular. The findings suggest morphea deserves the same oncologic scrutiny as its more studied cousin, systemic sclerosis.
Morphea — a localized form of scleroderma often considered benign — may not be as low-risk as once thought. A large Canadian study published in JAMA Dermatology found that patients with morphea have a significantly elevated cancer incidence compared to the general population, putting it in the same concerning territory as systemic sclerosis (SSc), a condition already known for its cancer associations.
Researchers analyzed data from over 6,000 morphea patients and 8,000 SSc patients tracked between 1996 and 2020. Both groups showed elevated overall cancer rates, with solid tumors being a shared risk. In morphea patients, female reproductive and breast cancers were the most common, while SSc patients faced a notably higher risk of hematologic cancers. Younger patients in both groups faced the highest relative risk.
By the Numbers:
Why it matters: Morphea has historically flown under the radar when it comes to cancer surveillance. These findings challenge that assumption, suggesting clinicians should consider proactive oncologic monitoring for morphea patients — especially younger individuals and those with female reproductive risk factors.